CL

Colgate-Palmolive Company -- The Essentials

Large-cap Consumer Discretionary company Colgate-Palmolive Company has moved -3.9% so far today on a volume of 6,982,573, compared to its average of 4,471,482. In contrast, the S&P 500 index moved 0.0%.

Colgate-Palmolive Company trades -6.49% away from its average analyst target price of $81.56 per share. The 18 analysts following the stock have set target prices ranging from $66.0 to $90.0, and on average have given Colgate-Palmolive Company a rating of buy.

If you are considering an investment in CL, you'll want to know the following:

  • Colgate-Palmolive Company has moved 1.9% over the last year, and the S&P 500 logged a change of 20.8%

  • Based on its trailing earnings per share of 1.91, Colgate-Palmolive Company has a trailing 12 month Price to Earnings (P/E) ratio of 39.9 while the S&P 500 average is 15.97

  • CL has a forward P/E ratio of 22.2 based on its forward 12 month price to earnings (EPS) of $3.43 per share

  • The company has a price to earnings growth (PEG) ratio of 3.3 — a number near or below 1 signifying that Colgate-Palmolive Company is fairly valued compared to its estimated growth potential

  • Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products worldwide.

  • Based in New York, the company has 33,800 full time employees and a market cap of $62.8 Billion. Colgate-Palmolive Company currently returns an annual dividend yield of 2.4%.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS